Back to News
Market Impact: 0.48
Vera's TRUTAKNA Shows Two-Year Kidney Protection; SBLA Planned Q4 2026; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Vera Therapeutics reported that TRUTAKNA stabilized kidney function and prevented disease progression over two years in adults with primary IgA nephropathy in the pivotal ORIGIN 3 trial. The positive long-term pivotal-study outcome materially strengthens the therapy's clinical profile and could support its commercial and regulatory outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
VERA0.90
More News
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Binance’s $6.3 Billion Cyber Heist Shows Crypto Vulnerabilities
- Big Oil Scores $56 Billion Windfall on Spiking Fuel Prices
- Chevron speeds ahead in Venezuela while Exxon urges caution with a ‘little pinch of salt’
- Backbone of a beast – charting Nvidia's rise to networking titan
- OpenAI raises just $11bn of $30bn target as AI investor appetite cools